金城医药(300233.SZ)发布上半年业绩，归母净利润4338.32万元，同比下降66.78%

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 1.36 billion yuan, a year-on-year decrease of 22.65% [1] - The net profit attributable to shareholders was 43.38 million yuan, reflecting a year-on-year decline of 66.78% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 38.73 million yuan, down 68.12% year-on-year [1] - Basic earnings per share were reported at 0.11 yuan [1]